Greens Senator Sarah Hanson-Young has slammed Liberal Democrat Senator David Leyonhjelm’s attempt to stay her defamation case against him without providing evidence that the alleged misandrist comments at the heart of the proceedings were spoken in Parliament.
A construction company has lost its appeal of a ruling that it illegally blocked CFMMEU officials from entering a work site to meet with union members, with a judge saying the union did not need to prove intent to obstruct to make its case for violations of the Fair Work Act.
Biotech company Cryosite has agreed to pay $1.05 million to settle the competition regulator’s landmark case alleging it jumped the gun on a proposed merger agreement with rival Cell Care.
A former Norton Rose Fulbright partner says he may file a contempt of court motion against the firm for allegedly failing to produce certain evidentiary documents for over two years.
Railway technology company Wavetrain Systems has asked the court to bar a competitor started by its former CEO from making allegedly false claims about its patented rail safety devices to clients.
A judge that rejected a bid by Sanofi-Aventis for an injunction blocking rival Alphapharm from listing an insulin injector pen on the PBS erred in his consideration of the harm it would face, the drug giant has told the Full Federal Court.
AMP executives are the focus of the Australian Securities and Investments Commission’s investigation of the wealth management firm’s fees for no service scandal, a court heard Friday.
Acciona Infrastructure and Transport for NSW are currently in settlement talks over a $1.2 billion dispute around the NSW government’s ongoing light rail project in Sydney.
Pharmaceutical giant Wyeth has shot down arguments by rival Merck Sharp & Dohme that its Prevnar 13 vaccine lacked inventiveness, saying during the closing submissions of a high-stakes patent trial that up until it developed the top-selling shot scientists thought there was a “ceiling” of 11 types of pneumococcal bacteria that could be included in a single vaccine.
A judge won’t defer the opt-out notice in a shareholder class action against GetSwift pending the High Court’s decision on a special leave application to revive a competing class action, saying the sooner the case settles the better.